Drug Trial Radar · NCT02370537
A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI
Last checked: Nov 20, 2026Latest source record: Jan 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
490
Actual
Start
Mar 2015
Primary completion
Nov 2015
Study completion Nov 2015
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 25, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a 2-part open-label, randomized, crossover, multicenter, non-therapeutic Phase II study to investigate the presence of pancreatic exocrine insufficiency (PEI) in patients with Type 2 diabetes mellitus (T2DM), and to investigate the pharmacokinetics (PK) of EPANOVA® (omega-3 carboxylic acids) and omega-3-acid ethyl esters (OMACOR®, Abbott Healthcare Products Ltd) following a single oral dose in patients with different degrees of PEI.
Conditions
- Diabetes Mellitus, Type 2
- Exocrine Pancreatic Insufficiency
Interventions
Epanova® (omega-3 carboxylic acids)Drug
4 g (administered orally as 4 x 1 g capsules)
Omacor® (omega-3-acid ethyl esters)Drug
4 g (administered orally as 4 x 1 g capsules)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Serum TG Level.Time frame: 7 days after enrollment.
- Part B: Baseline Corrected Area Under the Plasma Concentration Time Curve From Time Zero to Last Measurable Concentration (AUC[0-last]) for Total Eicosapentaenoic Acid (EPA) Following Administration of EPANOVA® and OMACOR®.Time frame: Blood samples for analysis were taken at 1, 0.5, and 0.05 hours pre-dose, to be used as baseline, and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 24 and 48 hours post-dose.
- Part B: Baseline Corrected AUC(0-last) for Total Docosahexaenoic Acid (DHA) Following Administration of EPANOVA® and OMACOR®.Time frame: Blood samples for analysis were taken at 1, 0.5, and 0.05 hours pre-dose, to be used as baseline, and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 24 and 48 hours post-dose.
- Part B: Baseline Corrected AUC(0-last) for Total EPA+DHA Following Administration of EPANOVA® and OMACOR®.Time frame: Blood samples for analysis were taken at 1, 0.5, and 0.05 hours pre-dose, to be used as baseline, and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 24 and 48 hours post-dose.
- Part B: Baseline Corrected Maximum Plasma Drug Concentration (Cmax) for Total EPA Following Administration of EPANOVA® and OMACOR®.Time frame: Blood samples for analysis were taken at 1, 0.5, and 0.05 hours pre-dose, to be used as baseline, and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 24 and 48 hours post-dose.
- Part B: Baseline Corrected Cmax for Total DHA Following Administration of EPANOVA® and OMACOR®.Time frame: Blood samples for analysis were taken at 1, 0.5, and 0.05 hours pre-dose, to be used as baseline, and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 24 and 48 hours post-dose.
- Part B: Baseline Corrected Cmax for Total EPA+DHA Following Administration of EPANOVA® and OMACOR®.Time frame: Blood samples for analysis were taken at 1, 0.5, and 0.05 hours pre-dose, to be used as baseline, and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 24 and 48 hours post-dose.
Locations
22 sites in 6 countries. Site status is shown where the registry gives one.
Research Site
Aarhus, Denmark
Research Site
Frederiksberg, Denmark
Research Site
København NV, Denmark
Research Site
Balatonfüred, Hungary
Research Site
Budapest, Hungary
Research Site
Létavértes, Hungary
Research Site
Daugavpils, Latvia
Research Site
Jēkabpils, Latvia
Research Site
Riga, Latvia
Research Site
Bialystok, Poland
Research Site
Puławy, Poland
Research Site
Staszów, Poland
Research Site
Zamość, Poland
Research Site
Bardejov, Slovakia
Research Site
Bratislava, Slovakia
Research Site
Ľubochňa, Slovakia
Research Site
Gothenburg, Sweden
Research Site
Linköping, Sweden
Research Site
Lund, Sweden
Research Site
Malmö, Sweden
Research Site
Stockholm, Sweden
Research Site
Uppsala, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.